Anti-inflammatory Effects of Homotaurine in Patients With Amnestic Mild Cognitive Impairment.

Front Aging Neurosci 2018 2;10:285. Epub 2018 Nov 2.

Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy.

Alzheimer's disease (AD) is a fatal dementing neurodegenerative disease, currently lacking an efficacious disease-modifying therapy. In the last years, there has been some interest in the use of homotaurine as a potential therapeutic compound for AD, but more work is still needed to prove its efficacy as disease modifier in dementia. Since inflammation is believed to play a key role in AD development, we sought to investigate here the homotaurine effect on inflammatory response in patients at the earliest stages of AD, i.e., suffering from amnestic mild cognitive impairment (aMCI). Thus, the present study aims to evaluate the effects of homotaurine supplementation on cytokine serum levels and memory performances in MCI patients. Neuropsychological, clinical and cytokine assessment was performed at baseline (T0) and after 1 year (T12) of homotaurine supplementation in 20 patients categorized as carriers ( = 9) or no carriers ( = 11) of the ε4 allele of the apolipoprotein E (APOE) gene, the strongest genetic risk factor for AD. The serum levels of the pro-inflammatory mediators Interleukin (IL) 1β, Tumor necrosis factor-alpha (TNFα), IL-6 and IL-18, contextually with the anti-inflammatory molecules IL-18 binding protein (IL-18BP) and Transforming growth factor-beta (TGFβ), were analyzed to explore significant differences in the inflammatory status between T0 and T12 in the two APOE variant carrier groups. No significant differences over time were observed in patients as for most cytokines, except for IL-18. Following homotaurine supplementation, patients carrying the APOEε4 allele showed a significant decrease in IL-18 (both in its total and IL-18BP unbound forms), in turn associated with improved short-term episodic memory performance as measured by the recency effect of the Rey 15-word list learning test immediate recall. Thus, homotaurine supplementation in individuals with aMCI may have a positive consequence on episodic memory loss due, at least in part, to homotaurine anti-inflammatory effects. This study strongly suggests that future research should focus on exploring the mechanisms by which homotaurine controls brain inflammation during AD progression.

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fnagi.2018.00285
Publisher Site
http://dx.doi.org/10.3389/fnagi.2018.00285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230970PMC
November 2018
52 Reads

Publication Analysis

Top Keywords

homotaurine supplementation
16
homotaurine
9
mild cognitive
8
cognitive impairment
8
amnestic mild
8
episodic memory
8
serum levels
8
supplementation patients
8
effects homotaurine
8
anti-inflammatory effects
8
patients
6
contextually anti-inflammatory
4
anti-inflammatory molecules
4
il-18 binding
4
binding protein
4
molecules il-18
4
il-6 il-18
4
necrosis factor-alpha
4
factor-alpha tnfα
4
tnfα il-6
4

References

(Supplied by CrossRef)
Inflammation and Alzheimer’s disease
Akiyama et al.
Neurobiol. Aging 2000
Interleukin 18 in the CNS
Alboni et al.
J. Neuroinflammation 2010

Similar Publications